Before clinical data became a cloud, a platform, or an input for an AI agent, it was paperwork. At the beginning of Raj Indupuri’s career, research sites recorded information on forms. Those forms could travel by FedEx or another courier. Then an army of people entered what they saw into databases. The workflow had all the elegance of moving a piano through a revolving door: possible, expensive, and dependent on many careful hands.
Indupuri arrived in the United States in 1997 and joined Serono as a clinical database developer. He had trained as a mechanical engineer in southern India, but a brush with programming during university had pulled him toward software. Databases, in particular, caught his attention. Here was engineering without steel, a discipline of structures that had to hold even when the contents became unruly.
The contents were certainly unruly. Clinical research produces data that must be collected, checked, reconciled, analyzed, and prepared for decisions. Each study can involve different sources, formats, vendors, and standards. A mistake does not merely spoil a dashboard. It can delay work across a tightly governed process. Indupuri found himself at the hinge between paper and electronic data capture, helping Serono teams replace manual steps with digital ones. It was an excellent place to develop a lifelong intolerance for avoidable friction.
A useful detour
Growing up in Andhra Pradesh, Indupuri looked up to his grandfather, an entrepreneur in a business family. He remembers him as a risk-taker who pushed boundaries. The influence stayed with him, although his own path began conventionally enough: mechanical engineering at Nagarjuna University in the early 1990s. Programming classes supplied the detour. He loved software engineering, took more computer science courses, and concentrated on database development.
The switch makes sense in retrospect, which is the unfair advantage of retrospection. At the time, it was simply fascination followed by effort. By 1997 he was learning an industry that joined technical puzzles to a clear purpose. He has said that people close to him in India had lacked access to advanced therapies. Working inside life sciences gave the abstractions of code a human destination. He decided to stay.
“Data is the currency of the industry.”Raj Indupuri
Currency is an interesting choice of word. Data can be valuable and still be irritatingly illiquid. A sponsor might spend heavily collecting it while lacking control over where it sits, how it is structured, or how quickly a reviewer can use it. Indupuri and his colleagues called the result “data chaos.” The phrase is blunt and accurate. A spreadsheet in one department may look orderly while the system around it remains a carnival of mismatched definitions.
The expanding data surface
Conceptual view, not a quantitative scale. Each transition improved access while adding sources, formats, and governance demands.
The division that wanted its own future
After Serono, Indupuri helped start eClinical Solutions as a life-sciences division of Eliassen Group, a technology consulting company. The new unit offered data management, acquisition, and statistical programming services to biotech and pharmaceutical clients. Indupuri took responsibility for its technology solutions. The team sat close enough to customer work to see the pattern: companies had adopted electronic systems, but their information was distributed across silos. Digitization had created data without automatically creating coherence.
The group began building software. That created a tidy corporate dilemma. Eliassen was a services and consulting business; enterprise software was not its central competence. Indupuri was passionate about the product and, with two partners, completed a management buyout. In 2012, eClinical Solutions emerged as an independent organization, and he began leading it as CEO.
There is no garage in this origin story and no ceremonial napkin covered in arrows. There is something more useful: a founder who learned the problem inside operating work, built a solution beside the customers who had it, and recognized when a side business needed a separate destiny. Entrepreneurship can look less like a lightning strike than a department refusing to remain a department.
Build the plumbing, then invite the intelligence
The company’s answer to data chaos became elluminate, a clinical data cloud designed to bring information from different sources and structures into a common environment. The platform and the company’s biometrics services form two halves of the same proposition: software supplies scale; people who understand clinical data supply context. The model resists the comforting fiction that difficult domain work can be solved by handing everyone a login.
The timing helped. Cloud infrastructure reduced the capital required to start and expand a software company. Indupuri has joked that a technology founder once needed millions for infrastructure, while the cloud era required an account and a credit card. He calls himself fortunate often: fortunate to land at Serono, to witness the electronic transition, to arrive at the cloud shift with a problem worth solving. Luck is his preferred vocabulary. Preparation keeps appearing in the grammar.
In 2020, Summit Partners invested in eClinical Solutions. In September 2024, GI Partners announced a majority investment, with Summit retaining a minority position and the founders keeping a significant stake. Indupuri remained CEO. The capital was intended to deepen the product roadmap, modernize the platform, and extend embedded AI capabilities. Ownership changed. The stated mission did not.
“A lot has changed over the years, but our mission hasn’t.”Raj Indupuri, 2024
The glass box test
AI has made Indupuri’s long-running argument newly fashionable and newly demanding. A model can flag anomalies, help map data, focus reviewers on exceptions, and reduce repetitive work. But clinical research is a poor setting for mystery. Teams need to know how a recommendation was produced, which information informed it, who reviewed it, and where responsibility sits. Indupuri’s phrase for the standard is a “glass box,” not a black box.
His 2026 diagnosis of stalled AI adoption has three parts. First, data must be ready. An agent perched on fragmented foundations will not create order. Second, governance and trust must be visible through lineage, explainability, and audit trails. Third, the operating model has to change. If a tool identifies the unusual cases but a team continues reviewing every record in the old way, the organization has purchased novelty without redesigning work.
This is a quieter AI thesis than the usual parade of synthetic miracles. It is also one an operator could use on Monday morning. Clean the foundation. Make the system legible. Change the workflow. Keep a person accountable. Indupuri is optimistic about what AI can do, but his optimism has spent thirty years in the company of databases. It has learned manners.
One problem, patiently observed
In 2021, PharmaVOICE named Indupuri among its annual group of 100 people recognized in life sciences. Co-founder Bob Arnesen described the early decision to take clinical data tasks into the cloud as a genuine risk and credited Indupuri’s conviction. The recognition captured an important feature of his career: he was not chasing one technical wave. He was watching waves strike the same beach.
Paper became electronic capture. Electronic systems multiplied. The cloud created a place to connect them. Machine learning found patterns within them. AI agents now promise to take action around them. At every stage, the attractive interface depends on unromantic work underneath: definitions, pipelines, permissions, standards, review, and trust.
Indupuri’s personal reading offers a neat footnote. In 2022 he had finished Zero to One, Peter Thiel’s account of creating something new, and was reading Jennifer Doudna and Samuel Sternberg’s A Crack in Creation, about a scientific tool with enormous possibilities and responsibilities. One book is about invention; the other is about judgment. His own work sits somewhere in that conversation.
By June 2026, he was speaking about continuous data review, real-time oversight, and the merging boundaries between clinical and real-world data. The nouns will continue changing. Indupuri’s verbs remain stubbornly consistent: acquire, connect, understand, decide. Three decades after the courier envelopes, he is still trying to shorten the distance between a fact being recorded and a responsible person being able to use it.
The future of clinical software may contain autonomous agents, continuous review, and interfaces that feel less like specialist machinery. It will also contain errors, exceptions, reluctant users, and meetings about definitions. Indupuri seems comfortable with both lists. He has built a career on the observation that progress is not the elimination of complexity. It is the patient design of systems that let people handle complexity without becoming its clerks.